Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in 'long COVID' patients with persistent dyspnoea.
COVID-19
viral infection
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
14
10
2021
accepted:
16
03
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
2
4
2022
Statut:
ppublish
Résumé
'Long COVID'-associated dyspnoea may persist for months after SARS-CoV-2 infection. Among the causes of persistent dyspnoea, dysfunctional breathing (DB), defined as an erratic or inappropriate ventilation at rest or exercise, has been observed, but little is known about its occurrence and pathophysiology among individuals with 'long COVID'. We aimed to describe the occurrence and identify clinical predictors of DB among patients following SARS-CoV-2 infection. Cardiopulmonary exercise testing (CPET) was performed in 51 SARS-CoV-2 patients (median age, 64 years (IQR, 15)); male, 66.7%) living with 'long COVID' and persistent dyspnoea. CPET was classified into three dominant patterns: respiratory limitation with gas exchange abnormalities (RL); normal CPET or O Among 51 patients, DB mostly without hyperventilation was found in 29.4% (n=15), RL in 54.9% (n=28) and D in 15.7% (n=8). When compared with RL individuals, patients with DB were younger, had significantly less severe initial infection, a better transfer capacity for carbon monoxide (median 85% (IQR, 28)), higher oxygen consumption (22.9 mL/min/kg (IQR, 5.5)), a better ventilatory efficiency slope (31.6 (IQR, 12.8)), and a higher SpO Our findings suggest that DB without hyperventilation could be an important pathophysiological mechanism of disabling dyspnoea in younger outpatients following SARS-CoV-2 infection, which appears to be a feature of COVID-19 not described in other viral diseases.
Sections du résumé
BACKGROUND
'Long COVID'-associated dyspnoea may persist for months after SARS-CoV-2 infection. Among the causes of persistent dyspnoea, dysfunctional breathing (DB), defined as an erratic or inappropriate ventilation at rest or exercise, has been observed, but little is known about its occurrence and pathophysiology among individuals with 'long COVID'. We aimed to describe the occurrence and identify clinical predictors of DB among patients following SARS-CoV-2 infection.
METHODS
Cardiopulmonary exercise testing (CPET) was performed in 51 SARS-CoV-2 patients (median age, 64 years (IQR, 15)); male, 66.7%) living with 'long COVID' and persistent dyspnoea. CPET was classified into three dominant patterns: respiratory limitation with gas exchange abnormalities (RL); normal CPET or O
RESULTS
Among 51 patients, DB mostly without hyperventilation was found in 29.4% (n=15), RL in 54.9% (n=28) and D in 15.7% (n=8). When compared with RL individuals, patients with DB were younger, had significantly less severe initial infection, a better transfer capacity for carbon monoxide (median 85% (IQR, 28)), higher oxygen consumption (22.9 mL/min/kg (IQR, 5.5)), a better ventilatory efficiency slope (31.6 (IQR, 12.8)), and a higher SpO
CONCLUSIONS
Our findings suggest that DB without hyperventilation could be an important pathophysiological mechanism of disabling dyspnoea in younger outpatients following SARS-CoV-2 infection, which appears to be a feature of COVID-19 not described in other viral diseases.
Identifiants
pubmed: 35354589
pii: 9/1/e001126
doi: 10.1136/bmjresp-2021-001126
pmc: PMC8968537
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Eur Respir J. 2021 Jan 28;57(1):
pubmed: 33361097
Eur Respir Rev. 2019 Dec 18;28(154):
pubmed: 31852745
Paediatr Respir Rev. 2015 Jan;16(1):53-61
pubmed: 25499573
Front Physiol. 2021 Jan 18;11:614590
pubmed: 33536937
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 34210791
EClinicalMedicine. 2021 Jan 07;31:100683
pubmed: 33490928
Eur Respir Rev. 2021 Apr 13;30(160):
pubmed: 33853883
Eur Respir J. 2017 Sep 11;50(3):
pubmed: 28893868
Eur Respir J. 2009 Feb;33(2):389-97
pubmed: 18768575
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 34385265
Expert Rev Respir Med. 2020 Jun;14(6):577-586
pubmed: 32168460
Front Physiol. 2021 Jan 27;11:620955
pubmed: 33584339
Chest. 1994 May;105(5):1365-9
pubmed: 8181321
Phys Ther. 2021 Jun 1;101(6):
pubmed: 33735374
Multidiscip Respir Med. 2021 Jan 25;16(1):732
pubmed: 33623700
Eur Respir Rev. 2021 Apr 13;30(160):
pubmed: 33853884
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054
Eur Respir Rev. 2016 Sep;25(141):287-94
pubmed: 27581828
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 33926969
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Am Rev Respir Dis. 1985 May;131(5):700-8
pubmed: 3923878
Ann Am Thorac Soc. 2021 Nov;18(11):1912-1917
pubmed: 33872135
Ned Tijdschr Geneeskd. 2020 Oct 29;164:
pubmed: 33331718
ACS Chem Neurosci. 2020 May 20;11(10):1379-1381
pubmed: 32348111